Blockchain Registration Transaction Record

ADAP Advocacy Calls for 340B Oversight Shift to CMS

ADAP Advocacy urges moving 340B Drug Pricing Program oversight from HRSA to CMS to enforce transparency and ensure revenues benefit low-income patients. Learn about the proposed reform.

This news matters because the 340B Drug Pricing Program affects the affordability and accessibility of prescription drugs for millions of low-income and underserved Americans. With $100 billion in annual sales and widespread lack of transparency, the program risks being exploited by hospitals and other covered entities that may not be using revenues to benefit patients. Moving oversight to CMS could enforce accountability, ensure that savings are reinvested into charity care, and ultimately protect patients who rely on the program for life-saving medications. For taxpayers and patients, this change could mean more efficient use of resources and better health outcomes.